Tag: R

Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.            About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s

InterDigital Joins Avanci IoT Licensing Platform

WILMINGTON, Del., Sept. 14, 2016 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile technology research and development company, today announced that it has joined Avanci, the industry’s first marketplace for the licensing of cellular standards-essential technology for the Internet of Things (IoT). The licensing platform brings together some of InterDigital’s peers in standards-essential technology leadership, and makes 2G, 3G and 4G standards-essential patents available to IoT players in specific product segments with one flat-rate license. “Avanci is a significant step forward in providing access to standards-essential patents for this new market, which is projected to see dramatic expansion in the

LifeSci Advisors Announces Opening of Office in Tel-Aviv, Israel

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) — LifeSci Advisors, a New York-based, life sciences focused investor relations consultancy, is pleased to announce today the opening of an office in Tel-Aviv, Israel.  The establishment of an Israeli office, together with the recent expansion of its European team, reflects LifeSci Advisors’ increasing international focus. Israel was selected as the location for LifeSci Advisors’ newest office due to the firm’s long-standing relationships with numerous companies and investors in Israel, together with Israel’s emergence as one of the world’s leading centers for life sciences. The Tel-Aviv office is being managed by Moran Meir Beres,

Synaptics Enhances Broad Automotive Portfolio with Three New Touch Controllers

SAN JOSE, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Synaptics Incorporated (NASDAQ:SYNA), the leading developer of human interface solutions, today announced three new feature-rich touch controller solutions designed specifically for the quality and reliability requirements and lifetime needs of the automotive market. The new Synaptics ClearPad® automotive solutions include S7880, S7881, and S7882 touchscreen controllers which address the rapidly advancing evolution of modern vehicle cockpits. Synaptics’ ClearPad automotive touch controllers harness the company’s deep expertise in human interface with features including pressure-sensing ClearForce™ technology, proximity detection, performance while wearing gloves, and performance under moist screen or finger conditions. Synaptics’ automotive

INC Research and CISCRP Announce Finalists for “Inspiring Hope” Ideathon

RALEIGH, N.C., Sept. 14, 2016 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicated to engaging the public and patients as partners in the clinical research process, today announced the finalists for the “Inspiring Hope” Ideathon event. In a competition that inspired nearly 70 entries, 14 ideas submitted by teams from around the world have been shortlisted for their potential to help address the critical need to increase awareness of clinical trial participation among

Greystone Provides $45 Million Bridge Loan for Acquisition of Tampa Multifamily Portfolio

NEW YORK, Sept. 13, 2016 (GLOBE NEWSWIRE) — Greystone, a real estate lending, investment and advisory company, today announced it has provided a $45,000,000 bridge loan for the acquisition of Tampa Woods Apartments (formerly known as Camden Woods Apartments), located in the Westshore district of Tampa, FL. The loan was originated by Donny Rosenberg of Greystone for Ilan Investments, the buyer. The non-recourse, interest-only bridge loan includes a two-year term with two six-month extensions and was closed in just 28 days. Tampa Woods Apartments, with an acquisition price of $58,000,000, is a Class A garden style apartment complex comprising 444

BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2)

BRANFORD, Conn., Sept. 13, 2016 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced that the U. S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BXCL101 for the treatment of Neurofibromatosis Type 2 (NF2), an orphan disease with significant unmet medical need.  BXCL101 is the first and only systemic therapy being developed to eliminate existing lesions and prevent the formation of new lesions by targeting the molecular mechanism of NF2 pathophysiology. BXCL101 is a proprietary version of an approved drug, bortezomib, adapted for chronic use in NF2 patients with both a

Pentaho Announces 2016 Excellence Award Winners

SAN FRANCISCO and ORLANDO, Fla., Sept. 13, 2016 (GLOBE NEWSWIRE) — Pentaho, a Hitachi Group Company, today announced the 2016 Excellence Award winners. The awards recognize the Pentaho customers responsible for the year’s most innovative and impactful implementations of Pentaho technology. Pentaho customers from around the world submitted their nominations in one of six categories, where the contest judges evaluated the submissions based on the creativity, impact and business value of the Pentaho deployment. This year’s judges’ panel included: Howard Dresner, Chief Research Officer, Dresner Advisory Services Greg Knieriemen, Technology Evangelist, Hitachi Data Systems Rosanne Saccone, Chief Marketing Officer, Pentaho,

ENT and Allergy Associates, LLP(R) Port Jefferson/East Patchogue, NY Practitioner Recognized for her Outstanding Contributions to the Field of Otolaryngology

TARRYTOWN, N.Y., Sept. 13, 2016 (GLOBE NEWSWIRE) — The ear, nose and throat specialists and sub-specialists of ENT and Allergy Associates (ENTA)-the nation’s preeminent otolaryngology practice-have long valued support offered to clinicians by the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). Year after year, so many of the Practice’s 180+ physicians attend the AAO-HNS annual meeting, this year to be held September 18-21 in San Diego, California.  Indeed, dozens of ENTA physicians have spoken and led seminars at AAO-HNS events held during the convention. This year is particularly special to ENTA, because one of its own-Dr. Lauren

Molecular Diagnostics Market To Reach $17.9 Billion By 2024: Grand View Research, Inc.

San Francisco, Sept. 13, 2016 (GLOBE NEWSWIRE) — Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their

TripAdvisor Applauds the United States Congress for Supporting the Consumer Review Fairness Act

NEEDHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — TripAdvisor®, a chief industry proponent for consumers’ rights, applauds the U.S. Senate and House of Representatives for seeking to protect travelers through their passage of the Consumer Review Fairness Act. If signed into law by the President after being reconciled with the version of the bill that was passed in the Senate, the legislation would protect consumers’ right to write online reviews about their travels on sites like TripAdvisor without facing the threat of retribution from businesses.   “TripAdvisor commends the work of Senator Thune and Congressmen Issa, Kennedy and Lance, and

SigmaTron International, Inc. Reports First Quarter Financial Results for Fiscal 2017

ELK GROVE VILLAGE, Ill., Sept. 12, 2016 (GLOBE NEWSWIRE) — SigmaTron International, Inc. (NASDAQ:SGMA), an electronic manufacturing services company, today reported revenues and earnings for the fiscal quarter ended July 31, 2016. Revenues decreased to $58.9 million in the first quarter of fiscal 2017 from $64.2 million for the same quarter in the prior year.  Net income of $146,597 was recorded for the quarter ended July 31, 2016 compared to net income of $658,806 for the same period in the prior year.  Basic and diluted earnings per share for the quarter ended July 31, 2016, were $0.04 and $0.03, respectively,

Energy

Huntington Ingalls Industries Continues to Make Strides on Aircraft Carrier John F. Kennedy (CVN 79)

NEWPORT NEWS, Va., Sept. 12, 2016 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE:HII) announced today that its Newport News Shipbuilding division placed a 900-ton superlift into dry dock, continuing construction of the nuclear-powered aircraft carrier John F. Kennedy (CVN 79). As Kennedy begins to take shape in the dry dock, the ship’s cost and construction schedule continue on track with significant improvement over its predecessor, the first-of-class Gerald R. Ford (CVN 78). “We continue to focus on reducing cost, and we are pleased with our progress,” said Mike Shawcross, Newport News’ vice president, CVN 79 carrier construction. “The incorporation of

Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant

MADISON, Wis., Sept. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple myeloma and preparing for a Phase 2 study in multiple myeloma and other hematologic malignancies, will be evaluated by the University of Wisconsin in combination with external beam radiation as a potential combination treatment for head and neck cancers (squamous cell carcinoma).  The research will be conducted as part of a Specialized Program of Research Excellence (SPORE) grant, awarded to the University of Wisconsin

Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development

NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsible for clinical development planning and strategy, including building and leading clinical teams to achieve the Company’s long-term strategic objectives, and will report to Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “Dr. Gardner’s extensive clinical and industry experience will be invaluable to Karyopharm as we continue forward with advancing our lead, novel, oral Selective Inhibitor of Nuclear Export (SINE™) compound,

Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement

Rockville, MD, Sept. 12, 2016 (GLOBE NEWSWIRE) — and Osaka, Japan, Sept. 12, 2016 — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced the conclusion of their License and Option Agreement for MGD010. MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period and follows Takeda’s recently announced therapeutic area re-prioritization.

Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem®

CLEVELAND, Sept. 12, 2016 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) announced today the successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing the commencement by HEALIOS K.K. (Healios) of a confirmatory clinical trial evaluating the safety and efficacy of administration of MultiStem®, Athersys’ novel cell therapy product, for the treatment of ischemic stroke in Japan (also designated by Healios as HLCM051 in Japan).  In accordance with the regulatory system in Japan, a CTN is equivalent to an Investigational New Drug application, or IND, under the regulatory system used in the United

Neurostimulation Devices Market Worth $9.8 Billion By 2024: Grand View Research, Inc.

San Francisco, Sept. 12, 2016 (GLOBE NEWSWIRE) — The neurostimulation devices market is expected to reach USD 9.8 billion by 2024, according to a new report by Grand View Research, Inc. The neurostimulation devices market is anticipated to witness a significant growth during the study period from 2016 to 2024. This growth is majorly attributed to high prevalence of chronic diseases, including migraine and epilepsy. Increasing adoption of unhealthy lifestyle, diet, and growth in aging population is resulting in a growing incidence of the chronic disease in individuals. However, adverse effects and risks associated with neurostimulation devices and presence of stringent

Amarin’s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee

BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2016 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the first pre-specified interim efficacy analysis for the REDUCE-IT cardiovascular outcomes study and has recommended that the trial continue as planned without modification. The 8,175-patient outcomes study is evaluating whether treatment with Vascepa® (icosapent ethyl) reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors. In accordance with the study protocol, the first interim efficacy analysis was performed after adjudication of

OHA Investment Corporation Announces New Credit Facility

NEW YORK, Sept. 09, 2016 (GLOBE NEWSWIRE) — OHA Investment Corporation (NASDAQ:OHAI) (the “Company”) today announced that it has closed a new $56.5 million secured term loan credit facility (“Credit Facility”) with MidCap Financial, which replaces the Company’s existing investment facility. Initial proceeds of $40.5 million from this Credit Facility were used to pay off the $38.5 million balance on our previous investment facility, pay transaction expenses and provide balance sheet cash. The remaining $16 million consists of a delayed draw term loan, which is committed for one year, and is available to OHAI to grow our investment portfolio and